Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2925 - Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer


11 Sep 2017


Poster display session


Breast Cancer


Francisco Ayala de la Peña


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


F. Ayala de la Peña, J.C. Yufera Soler, M.A. Ivars, A. Fernandez Sanchez, E. Navarro Manzano, P. De la Morena Barrio, E. Garcia-Garre, E. Garcia-Martinez, G. Marin Zafra, R. Salguero Aguilar, T. Garcia Garcia

Author affiliations

  • Hematology And Medical Oncology, Hospital Universitario Morales Meseguer, 30008 - Murcia/ES


Abstract 2925


Neutrophil-lymphocyte ratio (NLR) might be a surrogate marker of the tumor microenvironment immune balance and has been proposed as a prognostic factor for different tumors. A metanalysis of NLR for breast cancer (BC) showed that higher values at diagnosis were associated with lower survival. However, these results were mainly derived from the analysis of early BC cases: only three of twelve articles included women with metastatic breast cancer (MBC), sample size was small and no differential statistical analysis was performed for MBC. The aim of this work was to determine the prognostic value of NLR for MBC.


We retrospectively collected clinical and analytical data from a series of consecutive MBC patients treated in one center between 2009 and 2016. NLR (=neutrophil count/lymphocyte count) was obtained from differential white blood cell count at diagnosis of metastasis, before starting any treatment. Non-parametric tests (Mann Whitney U, Kruskal-Wallis) were used to evaluate differences of NLR between groups. Kaplan-Meier curves and Cox regression models (univariate and multivariate) were used for overall survival analysis.


265 consecutive patients with MBC were included, 117 of them (44%) with metastatic disease at diagnosis. Median age: 59 (19-95); ECOG 0-1 (69%), 2-3 (12%); site: bone only (37%), visceral only (18%), bone+visceral (30%); tumor subtype: HR (hormone receptor)+/HER2- (59%), HR+/HER2 + (17%), HR-/HER2 + (7%), HR-/HER2- (14%); disease free interval in recurrent MBC: 24 months (100, 67%). Outcomes: 135 deaths; median overall survival (OS): 35 months (IC95%: 27.4-42.6). Median NLR was 2.31 (range: 0.70-44.33), with significant higher values in women with ECOG 2-3 (p = 0.008) or negative estrogen receptors (p = 0.03). Univariate Cox model of OS showed a HR = 1.07 (95%: 1.03-1.11; p 


A higher NLR at diagnosis is a negative prognostic factor for overall survival in metastatic breast cancer. These data, if prospectively validated, may support the addition of NLR to MBC prognostic models and may lead to differential therapeutic approaches in patients with higher NLR.

Clinical trial identification

Legal entity responsible for the study

Francisco Ayala de la Peña




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.